EDDA Technology

Executive Summary

EDDA Technology is a US-based medical technology company specializing in AI-powered quantitative 3D imaging and surgical guidance platforms. Its flagship IQQA® platform provides end-to-end solutions for pre-surgical planning, intra-operative guidance, and post-operative assessment, primarily for cancer surgeries involving the liver, lung, and kidney. By leveraging advanced machine learning algorithms, EDDA aims to enhance precision, streamline workflows, and improve patient outcomes in minimally invasive and robotic surgical procedures. Founded in 2011 and headquartered in Princeton, New Jersey, the company has established itself as a key innovator in the surgical AI space, with potential for significant growth as hospitals increasingly adopt digital surgery technologies. EDDA’s solutions address critical needs in the rapidly expanding market for AI-assisted surgery. With the global surgical robotics market projected to exceed $20 billion by 2030, the demand for advanced intra-operative imaging and guidance tools is accelerating. EDDA’s ability to integrate with robotic systems and provide real-time, quantitative data positions it favorably to capture market share. Additionally, the growing emphasis on value-based care and precision medicine creates a strong tailwind for adoption. As the company continues to expand its clinical evidence base and pursue regulatory clearances globally, it is well-positioned to become a standard of care in complex cancer surgeries.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for IQQA platform in additional cancer indications (e.g., pancreatic or colorectal)70% success
• Q4 2026Strategic partnership or co-marketing agreement with a major surgical robotics company (e.g., Intuitive Surgical or Medtronic)60% success
• Q2 2027Publication of a large-scale clinical study demonstrating superior outcomes vs. standard of care for IQQA-guided liver or lung resections80% success